Franklin Murphy, MD
Infectious Disease · Reno, NVNPI 1437177516
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,316 of the $2,626 with a category attached, or 88.2%. It is spread thinly across 21 manufacturers, the largest accounting for just 20.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $646 and has fallen 57.5% since, to $275 in 2025.
Across 123 payments — averaging $21.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$541
- Viiv Healthcare Company$314
- Merck$282
- Astellas Pharma US Inc$251
- Gilead$237
- Pfizer$158
- plus $842 from 15 others
What the payments were for
- Food & beverage$2,31688%
- Education$31012%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 40 | $541 |
| Viiv Healthcare Company | 14 | $314 |
| Merck | 13 | $282 |
| Astellas Pharma US Inc | 4 | $251 |
| Gilead | 11 | $237 |
| Pfizer | 7 | $158 |
| Amgen(2 entities) | 3 | $138 |
| Paratek Pharmaceuticals, Inc. | 6 | $118 |
| Johnson & Johnson(2 entities) | 5 | $103 |
| Aimmune Therapeutics, Inc. | 4 | $88 |
| Insmed, Inc. | 3 | $79 |
| Shionogi Inc | 3 | $75 |
| Ferring Pharmaceuticals Inc. | 2 | $57 |
| Tetraphase Pharmaceuticals, Inc. | 1 | $31 |
| Biotissue Holdings Inc. | 1 | $30 |
| La Jolla Pharmaceutical Company | 1 | $28 |
| Theratechnologies Inc. | 1 | $24 |
| Bio Products Laboratory USA, Inc. | 1 | $21 |
| Vyera Pharmaceuticals, LLC | 1 | $19 |
| Cumberland Pharmaceuticals, Inc. | 1 | $18 |
| GSK | 1 | $15 |
How this compares
$2,626 in reported general payments places this provider in the 60th percentile of 65 infectious disease providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 12 | $46,387 |
| Daptomycin | 36 | $40,117 |
| Doxycycline Hyclate | 79 | $1,968 |
| Cephalexin | 62 | $823 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 43 | $678 |
| Cefazolin Sodium | 22 | $607 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 65 | $411 |
| Rifampin | 15 | $377 |
| Amoxicillin | 25 | $285 |
| Entecavir | 12 | $218 |
| Azithromycin | 14 | $143 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadGenvoya | $237 | $46,38712 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 65 infectious disease providers in Nevada.
Other infectious disease in Reno
- Elaine YeeReno$8K
- Thomas HovenicReno$7K
- Steven ParkerReno$6K
- Raymond SwartsReno$873
- Andres Adrianza PachecoReno$840
- Samuel LeeReno$412
- Natalie CrawfordReno$204
- Michael ZouReno$156
- Christina BaileyReno$149
- Jasmine DhindsaReno$125
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.